Cardiac medical device maker AtriCure (NASDAQ:ATRC) sees big opportunity in a new “hybrid” procedure that treats atrial fibrillation with a combination of ablation from inside and outside of the heart. But the Cincinnati-area company will likely have to wait awhile before it begins to cash in on what CEO David Drachman has called a $2 […]
The launch of a pivotal clinical trial next year for a “hybrid” procedure to treat atrial fibrillation patients will be an “inflection point” for cardiac surgical device maker AtriCure’s (NASDAQ:ATRC) U.S. business, its CEO said. The pivotal clinical trial, which could lead to regulatory approval of the hybrid procedure to treat atrial fibrillation and is […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
AtriCure (NASDAQ:ATRC) founder Michael Hooven‘s next project could change the way children are injected with vaccines. But you won’t hear that from him. Hooven politely declined to provide much detail on Cincinnati-based Enable Injections, saying that the company is still in its very early stages — though that could be changing soon. “In general, there […]
Cardiac surgical device maker AtriCure Inc. (NASDAQ:ATRC) has reported its first-ever profitable quarter as sales of its AtriClip device continue to climb. AtriCure's better-than-expected financial results sent its shares up in early trading.
Investment bank Roth Capital Partners has upgraded shares of AtriCure Inc. (NASDAQ:ATRC) to "Buy" and raised its target price by nearly 30 percent.
Cardiac medical device maker AtriCure Inc. (NASDAQ:ATRC) has enrolled the first patient in a clinical trial designed to test a hybrid procedure on patients with persistent atrial fibrillation, a condition marked by irregular heart rhythm. The procedure being evaluated in the study combines AtriCure's minimally invasive surgical ablation devices with a catheter-based ablation system from BioSense Webster, a Johnson & Johnson company.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Revenues continue to rise for medical device maker AtriCure Inc. (NASDAQ:ATRC), though the company still posted a net loss in the third quarter.
AtriCure Inc. (Nasdaq: ATRC) has agreed to pay $2.8 million to settle a class-action shareholder lawsuit that stems from claims that it promoted its surgical cardiac ablation devices for unapproved uses.
Riding high on an approval to sell a major new product in the United States, AtriCure Inc. (NASDAQ: ATRC) posted its smallest net loss ever during the second quarter — $764,506, or 5 cents a diluted share. A consensus of securities analysts surveyed by Thomson Reuters believed the company would lose 12 cents a share […]
Shares of West Chester, Ohio-based AtriCure Inc. (NASDAQ: ATRC) rose more than 20 percent Tuesday, a day after the Food and Drug Administration approved the company’s AtriClip system for sale in the United States. AtriCure shares rose as high as $7.20, ending the day up $1.07 at $6.30. More than 1 million AtriCure shares traded […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
AtriCure Inc. (NASDAQ: ATRC) has received regulatory clearance to begin U.S. sales of its AtriClip device, which protects against blood clots during certain heart procedures. The news sent AtriCure’s stock soaring 17 percent to $6.13 in early after-hours trading. The company plans an initial launch of the device later this month, with a full commercial […]
Updated 8:10 p.m., May 10, 2010. Atricure Inc. (NASDAQ: ATRC), the maker of cardiac surgical ablation systems, has received a conditional nod from the Food and Drug Administration (FDA) to evaluate the safety and efficacy of a hybrid procedure to treat patients with persistent forms of atrial fibrillation. The hybrid procedure “represents a key growth […]
Ohio’s medical device makers are still trying to figure out what the new 2.3 percent sales tax on their products–compliments of health care reform–will mean for them. The tax on sales by “manufacturers, producers or importers” (pdf) of medical devices comes due in 2013 instead of 2011, as was originally proposed, so companies have almost […]
US Endoscopy, the endoscopy device design and manufacturing company in Mentor, has released the Entrada colonic overtube, which offers more control during colonoscopy in patients with tortuous sigmoid looping.
Despite several challenges in 2009--like a Department of Justice investigation and related whistle-blower lawsuit--AtriCure Inc. advanced toward profitability, added regulator approvals for its cardiac surgical ablation systems and developed new avenues of growth.